CASI Pharmaceuticals, Inc.(NASDAQ : CASI)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Biotechnology
|REGN||Regeneron Pharmaceuticals, Inc.||1.91%||553.84||2.7%||$427.56m|
|SNSS||Sunesis Pharmaceuticals, Inc.||-2.48%||6.11||0.7%||$427.11m|
|GILD||Gilead Sciences, Inc.||1.54%||66.92||1.0%||$414.14m|
|XLRN||Acceleron Pharma, Inc.||0.25%||173.44||5.3%||$363.37m|
|VRTX||Vertex Pharmaceuticals, Inc.||1.61%||183.71||1.9%||$262.42m|
|XENE||Xenon Pharmaceuticals, Inc.||-0.81%||30.47||0.4%||$170.35m|
|CRSP||CRISPR Therapeutics AG||4.33%||100.38||0.6%||$160.89m|
CASI Pharmaceuticals, Inc. is a biopharmaceutical company, which is focused on the acquisition, development and commercialization of therapeutics addressing cancer and other unmet medical needs. The company develops and commercializes the oncology drugs and drug candidates in China, Taiwan, Hong Kong, and Macau. Its products include Zevalin, Evomela, and Marqibo. The company was founded in 1991 and is headquartered in Rockville, MD.